An interventional study of REBOA in Cardiopulmonary Arrest, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-28.
Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Heart Arrest by Seoul National University Hospital — 4 open to participants now, 5 under way, none of them phase 3. Heart Arrest · Seoul National University Hospital.
Among the 12 studies in Heart Arrest by Seoul National University Hospital, this one is the only one that started in 2023, is one of 8 with no phase, and was the 8th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →4 of the 12 studies in Heart Arrest by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages 18–50 · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 18+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 16+
By country, each count listing its studies:
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 234 is above the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 150 across the 8 interventional studies, 272 across the 4 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
Seoul National University Hospital is the lead sponsor of 1,903 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
1 of the studies in Heart Arrest by Seoul National University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07363772Seoul National University HospitalEvaluation of Mixed Reality Cardiopulmonary Resuscitation Training | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Heart Arrest by Seoul National University Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators propose a multicenter randomized controlled trial in South Korea and Taiwan to observe the clinical effects of REBOA on nontraumatic out-of-hospital-cardiac-arrest (OHCA) patients. While REBOA has been traditionally used in trauma for hemorrhage control, it has also shown promising results in nontraumatic cardiac arrests by rerouting circulation to increase perfusion in the coronary and brain.
Nontraumatic OHCA patients arriving at the 2 participating hospitals between the ages of 20 to 80 will be eligible. If the patient meets the enrollment criteria, he/she will be randomized into the control group (treatment with conventional ACLS according to the 2020 AHA guideline) or the REBOA group (ACLS according to the 2020 AHA guideline with REBOA application). A sheath catheter is inserted with ultrasound guidance to gain access to the common femoral artery in both groups. This is followed by insertion of the REBOA catheter, if the patient is allocated into the intervention group. The aortic balloon is inflated. If ROSC is achieved, the balloon is deflated slowly. Patients who achieve ROSC will receive post cardiac arrest management according to the 2020 AHA guideline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients allocated to this arm receives conventional resuscitative measures according to the 2020 AHA CPR Guidelines.
After enrollment and randomization, patients allocated to this arm receives REBOA in addition to conventional ACLS according to the 2020 AHA CPR guidelines. The common femoral artery is accessed with ultrasound guidance. A sheath catheter is inserted, followed by a REBOA catheter. The REBOA is ballooned with 20cc of normal saline or until resistance is felt.
Device: REBOA
Resuscitative endovascular balloon occlusion of the aorta (REBOA)is a device composed of a catheter attached to an inflatable balloon. It is inserted through the common femoral artery and guided to the thoracic aorta.
Number of Participants Who Achieved ROSC (return of spontaneous circulation)
Number of patients who achieves ROSC regardless of sustained time
Time frame: 24 hours
Number of Participants Who Achieved Sustained ROSC
Number of participants who achieves sustained ROSC (ROSC maintained more than 20 minutes)
Time frame: 24 hours
Survival to Admission
Whether patients who achieve sustained ROSC survives until admission
Time frame: 48 hours
Survival to Discharge
Whether patients survive until hospital discharge.
Time frame: 30 days
Neurological Outcome
The cerebral performance category (CPC) and modified Rankin Score (mRS) of each patient at 28 days, 3 months, and 6 months after achieving ROSC. CPC is measured on a scale of 1 to 5, with 1 being the best neurological performance, and 5 indicating brain death. MRS is measured on a scale of 0 to 6, with 0 indicating no neurological deficit, and 6 indicating death.
Time frame: 1 month, 3 months, 6 months since ROSC
Changes in Arterial Blood Pressure
Arterial blood pressure measured before and after REBOA inflation in the experimental group. Both systolic and diastolic pressures will be used.
Time frame: ABP 2 minutes and 1 minute before REBOA insertion, ABP 1 minute / 2 minutes / 4 minutes / 10 minutes after REBOA insertion.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Oct 2023 (actual). Primary completion is estimated for Oct 2025, 23 months after the start.
Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 23 months is below that.
Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →